Follows adults with platinum-resistant FRα-positive ovarian, tube or peritoneal cancer on mirvetuximab
Follows adults with ovarian-type cancer treated with mirvetuximab soravtansine in routine care.
Plain-language title generated from the registry record
Registry title: Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Key facts
- Where
- Vienna, AustriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
- Which best describes your most recent course of platinum chemotherapy (such as carboplatin or cisplatin)?
Source: NCT07896421, who can take part
Where in Austria
- Medizinische Universitaet Wien /ID# 282657Vienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT07896421
- Record updated
- 27 October 2026
- Original description
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm. The goal of this observational study is to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine.Read full original descriptionShow less
Multi-country Real-World Observational Study of MIrvetuximab Soravtansine in Treating Platinum-REsistant FRALphA Positive Ovarian, Fallopian Tube, and Peritoneal Cancer- MIRELA
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm. The goal of this observational study is to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine.
Mirvetuximab soravtansine (MIRV) is an approved antibody-drug conjugate being studied for the treatment of FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer. Adult participants with FRα-positive platinum-resistant cancer who have received 1-3 prior treatment lines and are scheduled to receive MIRV as monotherapy will be enrolled. Approximately 500 participants will be enrolled at sites globally.
Participants will receive intravenous infusions of mirvetuximab soravtansine as monotherapy according to the local product label and treating physician's decision. The total study duration per participant may be up to 18 months of follow-up.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion: Participants scheduled to be treated with mirvetuximab soravtansine in accordance with the local label, with treatment decision made independently before study enrollment; Signed informed consent and willingness to comply with study requirements including patient-reported outcome data collection.
Exclusion: Participation in a concurrent interventional clinical trial from enrollment throughout the study; Any condition included in the contraindications section of the approved local mirvetuximab soravtansine label; Unwillingness or inability to comply with study requirements.